KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026
KalVista Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Mar '24 Mar 31, 2024 | Apr '23 Apr 30, 2023 |
Cash & Equivalents | 213.77 | 229.34 | 131.62 | 31.79 | - | 56.24 |
Short-Term Investments | 71.26 | 70.87 | 89 | 178.61 | - | 93.14 |
Cash & Short-Term Investments | 285.03 | 300.21 | 220.62 | 210.4 | - | 149.38 |
Cash Growth | 63.55% | 36.08% | 4.86% | - | - | -10.12% |
Accounts Receivable | 9.9 | 2.59 | 11 | - | - | - |
Other Receivables | 7.43 | 8.71 | 4.14 | 10.87 | - | 18.64 |
Receivables | 17.33 | 11.3 | 15.14 | 10.87 | - | 18.64 |
Inventory | 4 | 3.43 | - | - | - | - |
Prepaid Expenses | 7.85 | 5.2 | 5.93 | 4.42 | - | 4.31 |
Total Current Assets | 314.21 | 320.15 | 241.69 | 225.69 | - | 172.33 |
Property, Plant & Equipment | 12.26 | 12.86 | 7.53 | 9.15 | - | 10.77 |
Other Long-Term Assets | 2.45 | 2.37 | 1.55 | 0.57 | - | 0.11 |
Total Assets | 328.92 | 335.38 | 250.77 | 235.4 | - | 183.2 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Mar '24 Mar 31, 2024 | Apr '23 Apr 30, 2023 |
Accounts Payable | 8.05 | 8.27 | 4.88 | 9.11 | - | 4.82 |
Accrued Expenses | 25.08 | 27.06 | 26.5 | 12.15 | - | 9.13 |
Current Portion of Long-Term Debt | 16.23 | 13.57 | - | - | - | - |
Current Portion of Leases | 1.69 | 1.62 | 1.98 | 1.3 | - | 1.09 |
Current Unearned Revenue | 0.83 | - | 11 | - | - | - |
Other Current Liabilities | 8.94 | 6.84 | 0.81 | 0.25 | - | - |
Total Current Liabilities | 60.82 | 57.36 | 45.17 | 22.81 | - | 15.03 |
Long-Term Debt | 255.98 | 258.29 | 105.88 | - | - | - |
Long-Term Leases | 10.41 | 10.73 | 4.33 | 6.02 | - | 7.15 |
Long-Term Unearned Revenue | 21.36 | 11.71 | - | - | - | - |
Total Liabilities | 348.57 | 338.09 | 155.38 | 28.82 | - | 22.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Mar '24 Mar 31, 2024 | Apr '23 Apr 30, 2023 |
Common Stock | 0.05 | 0.05 | 0.05 | 0.04 | - | 0.03 |
Additional Paid-In Capital | 773.59 | 767.06 | 753.73 | 679.75 | - | 507.13 |
Retained Earnings | -786.18 | -762.69 | -653.17 | -469.73 | - | -343.08 |
Comprehensive Income & Other | -7.12 | -7.13 | -5.21 | -3.49 | - | -3.06 |
Shareholders' Equity | -19.65 | -2.71 | 95.39 | 206.58 | - | 161.03 |
Total Liabilities & Equity | 328.92 | 335.38 | 250.77 | 235.4 | - | 183.2 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Mar '24 Mar 31, 2024 | Apr '23 Apr 30, 2023 |
Total Debt | 284.31 | 284.21 | 112.19 | 7.32 | - | 8.23 |
Net Cash (Debt) | 0.72 | 16.01 | 108.43 | 203.08 | - | 141.14 |
Net Cash Growth | -99.57% | -85.24% | -46.61% | - | - | -10.68% |
Net Cash Per Share | 0.01 | 0.30 | 2.18 | 5.52 | - | 5.06 |
Filing Date Shares Outstanding | 53.24 | 51.22 | 49.95 | 42.74 | - | 34.23 |
Total Common Shares Outstanding | 51.24 | 50.9 | 49.76 | 42.52 | - | 34.17 |
Working Capital | 253.39 | 262.79 | 196.52 | 202.88 | - | 157.29 |
Book Value Per Share | -0.38 | -0.05 | 1.92 | 4.86 | - | 4.71 |
Tangible Book Value | -19.65 | -2.71 | 95.39 | 206.58 | - | 161.03 |
Tangible Book Value Per Share | -0.38 | -0.05 | 1.92 | 4.86 | - | 4.71 |
Machinery | - | 4.51 | 3.23 | 2.81 | - | 3.05 |
Leasehold Improvements | - | 3.45 | 3.09 | 2.86 | - | 2.86 |